Lazar Mitchell A
Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, and The Penn Diabetes Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-6149, USA.
Biochimie. 2005 Jan;87(1):9-13. doi: 10.1016/j.biochi.2004.10.021.
It is now over 10 years since the discovery of peroxisome proliferator activated receptor gamma (PPAR gamma) and its unique role in adipogenesis. The subsequent identification of PPAR gamma as the target of insulin sensitizing drugs certified this ligand-regulated transcription factor as an exciting link between adipocyte biology and peripheral insulin resistance. Here, I summarize the great progress that has been made over the past decade in elucidating the biology of PPAR gamma and its role in adipogenesis and glucose metabolism. Prospects for future research leading to new therapies for obesity and diabetes are also discussed.
自发现过氧化物酶体增殖物激活受体γ(PPARγ)及其在脂肪生成中的独特作用以来,已经过去了10多年。随后将PPARγ鉴定为胰岛素增敏药物的靶点,证实了这种配体调节的转录因子是脂肪细胞生物学与外周胰岛素抵抗之间令人兴奋的联系。在此,我总结了过去十年在阐明PPARγ生物学及其在脂肪生成和葡萄糖代谢中的作用方面取得的巨大进展。还讨论了未来研究导致肥胖症和糖尿病新疗法的前景。